** Shares of Absci Corp ABSI.O rises 7.7% to $3.2 in
premarket trading
** Morgan Stanley initiates coverage on the AI biologics
firm with "overweight" rating and $7 price target, implying a
more than twofold upside to last close
** ABSI is using its artificial intelligence and machine
learning-enabled (AI/ML) platform to reduce costs and increase
point-of-sale for antibody therapies, MS says
** Collaborations with biopharma firms such as AstraZeneca
AZN.L in oncology and with Almirall ALM.MC in dermatology
validates ABSI's approach - brokerage
** "We see risk/reward skewed to upside at current levels
ahead of catalysts and updates that will provide significant
clarity into Absci's pipeline and platform efforts" - MS
** Five of six brokerages rate the stock "buy" and one
"hold"; median PT is $8 - LSEG data
** As of last close, ABSI down ~29% YTD vs S&P 500
Biotechnology index's .SPLRCTKBI ~6.4% gain during the period
(Reporting by Roshan Abraham)
((Roshan.Abraham@thomsonreuters.com))